



RTI Surgical Holdings, Inc.

Jonathon Singer
CF&AO

Molly Poarch
Director, IR & Corporate Communications

April 2019

Forward Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements.

In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rti.com or the SEC's website at www.sec.gov.

- Leading global surgical implant company
- Highly-regarded portfolio of biologic, metal, synthetic and synthetic-based implants
- Used in sports medicine, general surgery, spine, orthopedic and trauma procedures



Produces nearly **1,400** different types of implants



>8 MILLION biologic implants processed



~600,000 implants distributed in 2017 alone



Distributed in nearly **50 COUNTRIES**



~1,000 EMPLOYEES globally



Products used to treat **~500,000 PATIENTS** annually

Business Segments

OEM/Sports

**Spine/
International**

Leading Products

Tissue



Biologics



Synthetics



Metals



**World-Class
Global
Manufacturing**



Alachua, FL
106,000 sq. ft.



Marquette, MI
110,000 sq. ft.



Neunkirchen (DE)
~15,000 sq. ft.



Greenville, NC
~15,000 sq. ft.

RTI STRATEGY



BUSINESS STRATEGY

APPROACH

DESIRED OUTCOME } Build a growing and sustainably profitable business that will treat more patients, create growth opportunities for us and value for investors

Executing Our Strategic Transformation



Achieved significant progress across the three pillars of the strategic transformation, highlighted by recent strong financial performance

Reduce Complexity

Recent Activity

- Completed portfolio analysis
- Sold Cardiothoracic business ('17)
- Exited from tissue recovery ('18)

2019 Strategic Priorities

- + Focus on OEM and Spine portfolios
- + Simplify Sports channel

Drive Operational Excellence

Recent Activity

- Initiated aggressive \$25m cost reduction program in tissue
- Achieved >\$13m in cost savings to-date
- +200 bps Gross Margin in '18

2019 Strategic Priorities

- + On track to achieve \$25m in cost savings by end of 2019
- + Implementing lean manufacturing concepts across global manufacturing sites

Accelerate Growth

Recent Activity

- Rebuilt product pipeline across all franchises
- Acquired Zyga ('18) and Paradigm (closed in '19)
- Secured ViBone ('18)
- Launched Fortilink-TS and -L ('18)

2019 Strategic Priorities

- + Driving growth of core spine business and newly acquired / launched products
- + Graduate OEM partners to longer term contracts and focus on development of OEM pipeline

Paradigm Spine Acquisition Highlights

RTI acquired Paradigm Spine, a leader in motion preservation and non-fusion spinal implant technology



Paradigm Spine acquisition received shareholder approval on March 7, 2019



Operating as part of RTIX as of March 11, 2019



Cash and stock transaction valued at up to \$300 million, consisting of \$150 million at closing plus potential future milestone payments



Funded cash portion with approximately \$100 million in new, fully committed debt financing



Enters RTIX into lumbar spinal stenosis market with coflex®



\$40M Trailing 12 month revenue, ~90% Gross Margins



EBITDA accretive within 12 months of closing

Transaction Rationale

Investment in differentiated technology that closely aligns with RTI's M&A strategy

✓ Investing in differentiated high-growth products in spine market while building scale

✓ Adding proven asset with attractive market opportunity



✓ Leveraging additional sales channels with significant opportunity to maximize reimbursement pathways

✓ Continuing our focus on Europe; expanding Spine portfolio in strategic regions

Coflex[®]: Product Differentiation

First and only PMA motion preserving stabilization implant for the treatment of moderate to severe spinal stenosis in conjunction with decompression



\$3.3 Billion estimated market opportunity in Lumbar Spinal Stenosis



12+ years of clinical evidence established non-inferiority to fusion and superiority to decompression



High margin product profile



~1,300 trained surgeons and implanters



Approximately **50 Million** lives covered by Medicare and receiving expanded coverage from private payers, including in MI, SC, PA and ND



90+ peer reviewed studies; High quality FDA premarket approved study



Expanding coverage from payors sets stage for acceleration of growth



Significant clinical heritage and brand recognition

Unique Growth Strategy Coming to Life



Spine franchise has approximately doubled in size in the past five years



Acquiring Paradigm Spine accelerates RTI's growth strategy in Spine



Underscores significant ongoing progress toward completing strategic transformation



Deal closely aligns with RTI's M&A strategy



Focusing on differentiation and scale in Spine supported by OEM cash generation

Transaction highlights RTI's commitment to accelerating growth and driving shareholder value

Differentiated Portfolio Expansion


Advancing a full line of high-quality hardware, interbody and orthobiologic options



Acquisition of Paradigm Spine accelerates RTI's Spine strategy focused on differentiation and scale

Financial Overview

Full Year Revenue



Full Year Adjusted EBITDA



Targeting **<4x Debt / EBITDA** ratio by end of 2019

Long-term Goals

WITHIN FIVE YEARS:



Expand revenue to
>\$500M



Double EBITDA margin
to >20%



Reduction of complexity and operational excellence initiatives produce **improving margins and cash flow** in tissue operations



Improved financial performance funds **organic and acquisitive growth** in high margin spine focused operations

Investment Appeals

Achieved significant progress against strategic transformation highlighted by recent strong financial performance



Successfully executing strategic transformation



Investing in operational excellence



Driving margin enhancement



Investing in growth of spine franchise with focused R&D and targeted M&A



Producing organic growth



World class management team